Podcasts about biotech

In this episode of The Steward Chair, Maria Thacker Goethe, President and CEO of Georgia Life Sciences, shares her journey of transitioning from a dedicated "number two" to leading a massive ecosystem through a global pandemic. We explore how a commitment to mission and the guidance of mentors drives meaningful, long-term success even when the original plan is upended. We discuss the critical role of a connector in the life sciences sector, the importance of "work-life harmony" over balance, and why true stewardship means preparing the next generation to lead. This conversation provides actionable takeaways for leaders committed to stewardship, integrity, and impact. Key Takeaways Purpose Over Tactics: In times of crisis, your "North Star" must be your organizational purpose, allowing your tactics to remain nimble and adaptive. The Responsibility of Mentorship: Leadership is a societal responsibility; investing time in the next generation is essential because no leader is "here forever". Embracing "Ready Enough": You don’t have to feel fully ready to step into a leadership seat; surrounding yourself with a community that believes in you is the key to moving forward through fear. Resources Mentioned Visit https://www.galifesciences.org/ Follow Maria on LinkedIn at https://www.linkedin.com/in/mariathacker/ Join the Georgia Life Sciences mailing list at: https://www.galifesciences.org/join-the-mailing-list Join the ConversationThe Steward Chair is about equipping and inspiring business leaders to build organizations that stand the test of time. If this episode resonated with you, share your biggest takeaway and tag us on LinkedIn @ChatWithLeaders. Elevate your podcast, company meeting, or industry event strategies to better engage stakeholders and drive meaningful growth! Visit ChatWithLeaders.com to learn more about how we can help.See omnystudio.com/listener for privacy information.

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Big pharma and biotech take the earnings stage this week with reports from Eli Lilly (NYSE: LLNY) and Novo Nordisk (NYSE: NVO) leading the lineup. Will they help the industry once again outperform AI champ NVIDIA (NASDAQ: NVDA), as the industry did in 2025? Karl Thiel, Tom King, and Tim Beyers discuss: - Slow rolling chaos at FDA and its effects on drug approvals. - How to think about risk when investing in biotech. - Earnings predictions for Lilly and Novo as well as a review of results from DNA researcher Twist Bioscience (NASDAQ: TWST). Don't wait! Be sure to get to your local bookstore and pick up a copy of David's Gardner's new book — Rule Breaker Investing: How to Pick the Best Stocks of the Future and Build Lasting Wealth. It's on shelves now; get it before it's gone! Companies discussed: RGNX, LLY, NVO, TWST Host: Tim Beyers Guests: Karl Thiel, Tom King Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, and following his departure from LEO Pharma (see episode 164). Brian talks about new opportunities in obesity, the benefits of private ownership in funding early science, Boehringer's deal strategy, using AI to improve commercialization efforts, and the FDA's selection of zongertinib (in patients with HER2-mutant NSCLC) for the Commissioner's National Priority Voucher program.    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

The Nurses Report with David, Nicole & Ashley – Nurses examine the expanding intersection of biotech and Big Tech, raising urgent questions about health data, surveillance, and human dignity. As biologics, wearables, and corporate power converge, the conversation challenges listeners to consider consent, autonomy, and the spiritual cost of unchecked innovation in modern healthcare...

The Nurses Report with David, Nicole & Ashley – Nurses examine the expanding intersection of biotech and Big Tech, raising urgent questions about health data, surveillance, and human dignity. As biologics, wearables, and corporate power converge, the conversation challenges listeners to consider consent, autonomy, and the spiritual cost of unchecked innovation in modern healthcare...

Brant Peterson, Vice President & Fellow at Valo Health, joins Data in Biotech to explore how his team leverages real-world data, genetic insights, and machine learning to de-risk drug discovery. From building causal DAGs to identifying patient subtypes in neurodegenerative diseases like Parkinson's, this episode dives deep into a patient-first, data-driven approach to biomedical innovation. What You'll Learn in This Episode: >> How Valo Health uses real-world evidence and EHR data to prioritize drug targets earlier in the development pipeline. >> Why integrating wet lab experiments and causal DAGs accelerates therapeutic validation. >> The importance of genetic pleiotropy and Mendelian randomization in refining disease hypotheses. >> How Valo Health identifies high-impact patient subgroups in neurodegenerative diseases like Parkinson's and Alzheimer's. >> Where machine learning models succeed and fall short, in uncovering mechanisms of disease from sparse longitudinal data. Meet Our Guest Brant Peterson is Vice President & Fellow in Data Science at Valo Health. He brings deep expertise in genetics, computational biology, and biomedical innovation. Formerly a Distinguished Data Scientist at Valo and Computational Biologist at Novartis, Brant focuses on leveraging patient-centric data to drive causal discovery in drug development. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Brant Peterson on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Business - Armon Sharei | Portal Founder & CEO, Biotechnologies Leader

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world's largest privately held pharma companies, Brian Hilberdink's journey is anything but conventional. Live from JPM 2026 in San Francisco, Biotech 2050 host Alok Tayi sits down with the President, U.S. Human Pharma at Boehringer Ingelheim to explore how frontline sales experience shaped a career now steering launches across obesity, chronic kidney disease, oncology, and rare disease. The pair dive into Boehringer's long-term, privately held model—one that reinvests nearly 30% of revenue into R&D—and the strategic thinking behind its ambitious pipeline: first-in-class breakthroughs in interstitial lung disease, major obesity programs, and upcoming waves of launches through 2027 and beyond. They also unpack the future of commercial pharma—from direct-to-consumer models and digital patient engagement to AI-powered launches and trial recruitment—plus Brian's candid views on China's innovation engine and the growing importance of rare disease. A masterclass in modern pharma leadership, portfolio strategy, and building for generations. Biography: Brian Hilberdink is an accomplished global executive with over 25 years of leadership experience in the pharmaceutical industry, currently serving as President of U.S. Human Pharma at Boehringer Ingelheim. In his role at Boehringer, he oversees several business units across multiple therapeutic areas, including cardiometabolic and renal diseases, obesity, pulmonary fibrosis (ILD), and oncology. Renowned for driving impactful results and fostering cultures of accountability and engagement, Brian consistently enhances organizational performance. Previously, Hilberdink served as Executive Vice President at LEO Pharma, where he led the North American Region and served as President of the U.S. affiliate, which became the primary growth driver for the company globally.. Earlier in his career, Hilberdink held several senior-level positions at Novo Nordisk, where he worked across multiple geographies. He was recognized for developing and executing innovative go-to-market strategies, resulting in the successful launch of multiple blockbuster therapies in the areas of obesity and diabetes.

Send us a textAre GLP-1 drugs becoming a long-term foundation of healthcare? In this clip from our episode "What JPM Signals for Healthcare in 2026", CareTalk hosts David Williams and John Driscoll discuss why GLP-1s may be evolving beyond short-term weight loss treatments.Listen to the full episode here

How can biotech teams move faster (and smarter) from preclinical research to human trials without sacrificing safety or rigor? In this episode, host Elaine Hamm, PhD, sits down with Todd Kilbaugh, MD, Founder of Pharos Biolabs and a physician-scientist specializing in anesthesiology, critical care, and pediatrics. Todd shares his journey from clinical medicine to biotech entrepreneurship and unpacks one of the industry's toughest challenges: why so many promising therapies fail to translate from animal models to humans. Together, they explore how AI, advanced modeling, organoids, and more thoughtful use of non-human primates could reshape preclinical development and reduce costly failures. In this episode, you'll learn: Why the translational gap between animal models and humans remains one of biotech's biggest bottlenecks, and how AI can help close it. How biomarkers, mathematical modeling, and digital twins can improve trial design long before a therapy reaches the clinic. What the future of preclinical development could look like with smarter integration of AI, organoids, and non-human primate studies. Tune in for a wide-ranging conversation on AI-enabled science, better trial prediction, and how biotech can rethink the path from discovery to patients. Links: Connect with Todd Kilbaugh, MD. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Doug Wallace, PhD. Learn more about TBI. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This Biotech CEO Is Creating Advanced & Personalized Therapies To Fight Cancer.Full Name: Thomas JensenTitle: Chief Executive Officer, Allarity Therapeutics Ticker: $ALLRWebsite: https://www.allarity.com/Bio:Thomas Jensen is the Chief Executive Officer of Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage biopharmaceutical company advancing personalized cancer therapies. He was appointed CEO in December 2023 after nearly a decade as Chief Technology Officer, during which he helped pioneer the company's proprietary Drug Response Predictor (DRP®) platform.With over 20 years in the biotech and precision medicine space, Thomas has led Allarity through a focused strategic transformation centered on stenoparib—a first-in-class dual PARP/tankyrase inhibitor currently in Phase 2 trials for advanced ovarian cancer. Under his leadership, Allarity has achieved FDA Fast Track designation, formed key research collaborations, and presented clinical data showing landmark median overall survival of ovarian cancer patients.Company Bio:Allarity Therapeutics (NASDAQ: ALLR) is a clinical-stage biopharma company developing personalized cancer treatments guided by its proprietary DRP® companion diagnostic platform. The company's lead asset, stenoparib, is a novel, orally available dual PARP and WNT pathway inhibitor being evaluated in Phase 2 trials for advanced ovarian cancer. With headquarters in the U.S. and a research facility in Denmark, Allarity is committed to improving patient outcomes through precision oncology. Learn more at www.allarity.com

Strong launches, positive sentiment, flowing capital, and favorable macro and policy indicators: the signals remain strong as the biotech sector enters 2026. Yet investors may need to search harder for opportunities this year, according to new RBC research. Brian Abrahams, Head of Global Healthcare Research, highlights some of the classes set for new breakthroughs, and points to the potential tripwires that lie ahead as biotech looks to continue its near-historic rally.

As the new year settles in, the industry is anticipating new innovative biotech and learning from past failures. John Keilty, venture partner at Third Rock Ventures, discusses the current trends he sees in biopharma investment, separating the hype from reality of AI (and if the AI bubble will eventually pop), other ventures that should be considered, and how new companies are being built today compared to past years in this episode of Trends from the Trenches. With host Eleanor Howe, founder and CEO of Diamond Age Data Science, Keilty also reflects on the biotech failures of past years and shares his thoughts on the role of computational biologists these days, as well as where bioinvesting is working and not working now. Links from this episode:   Bio-IT World BioTeam Bio-IT World Europe Diamond Age Data Science Third Rock Ventures  Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he's now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode of the BioCentury This Week podcast, Director of Biopharma Intelligence Stephen Hansen and colleagues discuss Hansen's 2026 Public Markets Preview, which found interest rates, policy in Washington and fundamentals finally aligning and a wave of launches and M&A that could keep capital flowing into the sector.View full story: https://www.biocentury.com/article/658154#BiotechBullMarket #PublicMarkets #BiotechMA #IPOOutlook #FDApolicy00:00 - Introduction00:41 - Market Sentiment07:55 - Biotech's Next Wave14:47 - Lingering Concerns23:29 - IPOs26:47 - M&ATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Send us a textAI, GLP-1s, federal policy, and China. Those themes dominated last week's JP Morgan Health Care Conference in San Francisco. But what, if anything are the implications for the broader healthcare world in 2026?Hosts David Williams, President of Health Business Group, and John Driscoll, Chairman of UConn Health discuss what stood out most at JPM, including why the GLP-1 wave may be entering a new phase, how Big Tech and AI are reshaping the healthcare landscape, and why China's growing presence in biotech is becoming harder to ignore.

Value: After Hours is a podcast about value investing, Fintwit, and all things finance and investment by investors Tobias Carlisle, and Jake Taylor. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Soldier of Fortune: Warren Buffett, Sun Tzu and the Ancient Art of Risk-Taking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Kindle⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠)We are live every Tuesday at 1.30pm E / 10.30am P.See our latest episodes at https://acquirersmultiple.com/podcastAbout Jake Jake's Twitter: https://twitter.com/farnamjake1Jake's book: The Rebel Allocator https://amzn.to/2sgip3lABOUT THE PODCASTHi, I'm Tobias Carlisle. I launched The Acquirers Podcast to discuss the process of finding undervalued stocks, deep value investing, hedge funds, activism, buyouts, and special situations.We uncover the tactics and strategies for finding good investments, managing risk, dealing with bad luck, and maximizing success.SEE LATEST EPISODEShttps://acquirersmultiple.com/podcast/SEE OUR FREE DEEP VALUE STOCK SCREENER https://acquirersmultiple.com/screener/FOLLOW TOBIASWebsite: https://acquirersmultiple.com/Firm: https://acquirersfunds.com/ Twitter: ttps://twitter.com/GreenbackdLinkedIn: https://www.linkedin.com/in/tobycarlisleFacebook: https://www.facebook.com/tobiascarlisleInstagram: https://www.instagram.com/tobias_carlisleABOUT TOBIAS CARLISLETobias Carlisle is the founder of The Acquirer's Multiple®, and Acquirers Funds®. He is best known as the author of the #1 new release in Amazon's Business and Finance The Acquirer's Multiple: How the Billionaire Contrarians of Deep Value Beat the Market, the Amazon best-sellers Deep Value: Why Activists Investors and Other Contrarians Battle for Control of Losing Corporations (2014) (https://amzn.to/2VwvAGF), Quantitative Value: A Practitioner's Guide to Automating Intelligent Investment and Eliminating Behavioral Errors (2012) (https://amzn.to/2SDDxrN), and Concentrated Investing: Strategies of the World's Greatest Concentrated Value Investors (2016) (https://amzn.to/2SEEjVn). He has extensive experience in investment management, business valuation, public company corporate governance, and corporate law.Prior to founding the forerunner to Acquirers Funds in 2010, Tobias was an analyst at an activist hedge fund, general counsel of a company listed on the Australian Stock Exchange, and a corporate advisory lawyer. As a lawyer specializing in mergers and acquisitions he has advised on transactions across a variety of industries in the United States, the United Kingdom, China, Australia, Singapore, Bermuda, Papua New Guinea, New Zealand, and Guam. He is a graduate of the University of Queensland in Australia with degrees in Law (2001) and Business (Management) (1999).

Comment passer d'un doctorat en biochimie à un rôle stratégique dans l'industrie biotech ? Dans cet épisode de Beyond the Thesis with Papa PhD (en français), Yamina Berchiche partage son parcours riche et atypique : chercheuse, leader en startup, fondatrice de Doctor GPCR, conseillère stratégique en pharmacologie, et créatrice de communauté. Yamina revient sur les défis de l'après-PhD, les apprentissages de ses expériences en laboratoire et en startup, et sur l'importance d'identifier ses forces pour pivoter en toute confiance vers des rôles hors-académiques. Elle aborde aussi la place du réseautage dans une carrière scientifique, même quand on est introverti·e ou ambiverti·e. Vous apprendrez : • Comment repérer et utiliser vos compétences transférables • Ce que le leadership en startup lui a appris • Pourquoi bâtir une communauté peut transformer une carrière • Des stratégies concrètes pour réseauter sans s'épuiser • Comment évoluer vers une carrière alignée avec vos valeurs

In this special episode of the Prime Venture Partners Podcast, the Partners come together to discuss how AI, new business models, and shifting global dynamics are reshaping startups and what founders should be preparing for as we head deeper into 2026 and beyond. From pragmatic AI adoption to new opportunities in services, SaaS, climate, and governance, this is a grounded conversation on what's actually changing and what still matters.⏱️ Timestamps:00:00 – Introduction01:30 – What Prime Is Willing to Bet On03:20 – AI Models vs Real Value Creation07:35 – Automation, Services and Opportunity11:30 – Moats and Distribution in an AI-First World20:00 – Why Fundamentals Still Matter24:05 – SaaS, Services and India's Global Opportunity28:25 – How AI Will Change Venture Capital37:40 – Predicting the Defining Startups of 203042:05 – Climate, Energy and Big Problems Becoming Solvable45:40 – Boards, Governance and AI Ethics52:10 – Closing Thoughts for Founders Building in 2026

Trying to form early biotech partnerships but unsure when to say yes, when to push back, or when to walk away? In this episode, host Elaine Hamm, PhD, welcomes back Renee Williams, PhD, MBA, returning to the show as Chief Business Officer at Signify Bio. Drawing from her experience on both sides of the table (as a pharma dealmaker and now an early-stage biotech leader) Renee shares hard-earned insights on how founders can approach partnerships strategically without losing focus, time, or control of their company's story. In this episode, you'll learn: How to evaluate early partnership opportunities and decide which ones are worth your limited time, capital, and attention. Why focus is the most valuable currency for early-stage biotech, especially for platform companies facing constant “what else could this do?” questions. Practical guidance on MTAs, pilot studies, and proof-of-concept work, including how to structure collaborations so they move you closer to a real deal—not just more experiments. Whether you're navigating your first pharma conversation or refining how you partner as a growing biotech company, this episode offers clear, experience-driven advice to help you build partnerships that accelerate progress instead of distracting from it. Links: Connect with Renee Williams, PhD, MBA, and check out Signify Bio. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out our previous episode with Renee. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When Patricia Weltin's daughters were diagnosed with Ehlers-Danlos Syndrome after years of uncertainty, she turned her frustration into a global movement. In this episode of Sounds of Science, Patricia shares the story behind Beyond the Diagnosis, a powerful art and advocacy initiative that uses portraiture to humanize rare diseases and inspire empathy in medical professionals, students, and communities around the world. From medical schools to courthouses and even Parisian galleries, the traveling exhibit is reshaping how we see children with rare diseases—not as diagnoses, but as vibrant individuals with stories worth telling. Tune in to hear how Patricia's mission is bridging the gap between science and compassion, and how you can help carry it forward.Show NotesFrom Mystery to Medicine: The Science Behind a Mother's Search | PodcastTaking a Customized and Collaborative Approach to Therapeutic Development | PodcastRare Disease Research for Drug Development | Charles RiverRare Disease | Charles RiverDiscovery | Charles RiverBeyond The Diagnosis

We love to hear from our listeners. Send us a message. The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials. Brian talks about why he selected BPD as a lead clinical indication (a disease primarily affecting preterm infants), what he learned through founding and selling a CRO, how a private biotech funds a pivotal trial across continents, and offers an industry outlook for 2026.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Technology and health care futurist Jamie Metzl joins Howard Schweitzer, chief executive officer of Cozen O'Connor Public Strategies, for a wide-ranging conversation on the amazing technological revolutions defining our era. As artificial intelligence, genetics, and biotechnology converge at unprecedented speed, the time between transformative revolutions—from fire and agriculture to industrialization and now AI—continues to shrink. Together, they explore what this superconvergence means for humanity, why innovation is accelerating faster than our institutions, and how the choices made today will shape the future of civilization.

In this episode of the Real Estate Pros podcast, host Micah Johnson interviews Anton Dormer, the founder of BioLabShare, a pioneering co-living and co-working life science community in Huntsville, Alabama. Anton shares his background in chemistry and medicine, and how he identified a gap in affordable lab space for biotech entrepreneurs. The conversation explores the vision behind BioLabShare, the challenges faced in merging real estate with life sciences, and the importance of building a supportive ecosystem for innovation. Anton also discusses the significance of networking and collaboration in attracting startups to the community, as well as investment opportunities for interested parties.   Professional Real Estate Investors - How we can help you: Investor Fuel Mastermind:  Learn more about the Investor Fuel Mastermind, including 100% deal financing, massive discounts from vendors and sponsors you're already using, our world class community of over 150 members, and SO much more here: http://www.investorfuel.com/apply   Investor Machine Marketing Partnership:  Are you looking for consistent, high quality lead generation? Investor Machine is America's #1 lead generation service professional investors. Investor Machine provides true 'white glove' support to help you build the perfect marketing plan, then we'll execute it for you…talking and working together on an ongoing basis to help you hit YOUR goals! Learn more here: http://www.investormachine.com   Coaching with Mike Hambright:  Interested in 1 on 1 coaching with Mike Hambright? Mike coaches entrepreneurs looking to level up, build coaching or service based businesses (Mike runs multiple 7 and 8 figure a year businesses), building a coaching program and more. Learn more here: https://investorfuel.com/coachingwithmike   Attend a Vacation/Mastermind Retreat with Mike Hambright: Interested in joining a "mini-mastermind" with Mike and his private clients on an upcoming "Retreat", either at locations like Cabo San Lucas, Napa, Park City ski trip, Yellowstone, or even at Mike's East Texas "Big H Ranch"? Learn more here: http://www.investorfuel.com/retreat   Property Insurance: Join the largest and most investor friendly property insurance provider in 2 minutes. Free to join, and insure all your flips and rentals within minutes! There is NO easier insurance provider on the planet (turn insurance on or off in 1 minute without talking to anyone!), and there's no 15-30% agent mark up through this platform!  Register here: https://myinvestorinsurance.com/   New Real Estate Investors - How we can work together: Investor Fuel Club (Coaching and Deal Partner Community): Looking to kickstart your real estate investing career? Join our one of a kind Coaching Community, Investor Fuel Club, where you'll get trained by some of the best real estate investors in America, and partner with them on deals! You don't need $ for deals…we'll partner with you and hold your hand along the way! Learn More here: http://www.investorfuel.com/club   —--------------------

We kick off our CPG series with Dr. Erin Marasco, Senior Director of Global Biology at Cargill, who leads innovation in ingredient discovery, strain development, and biotech applications. Erin takes us on a fascinating journey from the fundamentals of fermentation to the complexities of scaling biotech products from lab bench to global supply chains. We explore Cargill's 30-year history in biomanufacturing, discuss why terms like "precision fermentation" might be doing more harm than good, and learn what it really takes for startups to partner with multinational companies. Erin shares insights on feedstock diversity across continents, the future of nutritional bioactives in everyday foods, and why success in biotech means moving from "novel" to "preferred." This conversation is essential listening for anyone interested in how biology is quietly transforming every aisle of the grocery store.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:(00:00:00) - Introduction & New Year Kickoff — Welcome to 2026 and the start of our CPG series!(00:01:00) - JP Morgan Conference & South Africa Travel(00:05:00) - New Food Pyramid Controversy(00:10:00) - Introducing Erin Marasco & Cargill's Role in Biotech(00:17:00) - Where Biotech Creates Real Leverage at Cargill(00:21:00) - Demystifying Fermentation: Why Now?(00:26:00) - How Cargill Partners with Startups(00:30:00) - Biggest Misconceptions About Working with Big Companies(00:33:00) - What Product Readiness Means to Cargill(00:38:00) - Plasmids to Pallets: Successful Partnership Examples(00:47:00) - Feedstock Diversity Across Continents(00:53:00) - The Future: Nutrition as Everyday Food(00:58:00) - Quick Fire Questions & Retiring "Precision Fermentation"(01:03:00) - Wrap-Up & What's Next in the CPG SeriesLinks and Resources:CargillCargill Fermentation BlogFermentation: nature's original biotech by CargillCantabria Labs (sunscreen from plant extracts)Viro - Sugarcane StrawsSawubona Mycelium Heliocare Cantabria Labs Andreesen Horowitz, VC fund, raised a $15 billion Topics Covered: biotech, industry, biomanufacturing, bioprocessing, agriculture, agritech, strain engineering, biotech R&D, feedstocks, chemical engineering, bioengineeringHave a question or comment? Message us here:Text or Call (804) 505-5553 Music by: Nihilore Production by:  Amplafy Media

What's really happening in biotech right now, and where should innovators and investors be paying attention? In this market update episode, host Elaine Hamm, PhD, is joined by guest host Travis Manasco, MD, for a candid conversation on the current state of biotech investing. Together, they unpack where momentum is building, where enthusiasm is cooling, and how founders, scientists, and investors should think strategically as the market finds its footing. From GLP-1s and AI to women's health and preclinical challenges, this episode offers a clear-eyed look at today's biotech landscape—just in time for JPM. In this episode, you'll learn: Which biotech sectors are heating up and why areas like obesity, AI-enabled clinical trials, and women's health are drawing renewed interest Why early-stage and preclinical innovation remains a tough funding environment, despite long-term opportunity How market signals like acquisitions and JPM dynamics may shape biotech strategy in the year ahead Tune in for an honest, insightful market conversation that cuts through the hype and helps you think more clearly about where biotech is headed next. Links: Connect with Travis Manasco, MD, and check out Solas BioVentures. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out the JP Morgan Healthcare Conference 2026. Check out our previous episode with Travis on AI in Medicine. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Daniel Garza had momentum. Acting roles, directing gigs, national tours lined up. Then anal cancer stopped everything. Radiation wrecked his body, stripped him of control, and left him in diapers, staring down despair. His partner, Christian Ramirez, carried him through the darkest nights, changed his wounds, fought hospitals, and paid the price with his own health. Christian still lives with permanent damage from caregiving, but he stayed anyway.Together they talk with me about masculinity, sex, shame, friendship, and survival. They describe the friendships that vanished, the laughter that kept them alive, and the brutal reality of caregiving no one prepares you for. We get into survivor guilt, PTSD, and why even rocks need rocks. Daniel is now an actor, director, and comedian living with HIV. Christian continues to tell the unfiltered truth about what it takes to be a caregiver and stay whole. This episode gives voice to both sides of the cancer experience, the survivor and the one who stands guard. RELATED LINKSDaniel Garza IMDbDaniel Garza on InstagramDaniel Garza on FacebookChristian Ramirez on LinkedInLilmesican Productions Inc (Daniel & Christian)Stupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks' shift to a royalty model for development funding and value creation, lessons learned from platform deals and cross-border R&D, the benefits of strong royalty agreements and backloaded milestone payments over headline upfronts, and industry dynamics for the coming year. Ken also shares insights from his deep experiences as a biotech investor and corporate director, and explains why scientific primacy should always drive biotech business decisions.         Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

This Biotech CEO Wants To Cure Lung Cancer – Maria Zanes President & CEO bioAffinity Technologies BIAF Ticker: BIAF Websitehttps://bioaffinitytech.com/Maria Zannes, Chief Executive Officer, President, and Director, bioAffinity Technologies, Inc. (NASDAQ: BIAF)BioSince founding bioAffinity Technologies in 2014, Ms. Zannes has built a team of award-winning scientists and executives who are advancing breakthrough diagnostics for lung cancer and other pulmonary diseases. The company's first commercial product, CyPath® Lung, is a noninvasive, accurate test for early-stage lung cancer that has proven to detect the disease as early as Stage 1A when it can be cured. Prior to bioAffinity Technologies, Ms. Zannes founded The Zannes Firm to provide strategic solutions for private industry in the medical, environmental and energy fields. Previously, she was President of the Energy Recovery Council, a national trade group and General Manager of ECOS Corporation, a subsidiary of Burlington Environmental. Earlier in her career, she was a legislative aide to Congressman Charles Wilson (D-TX) after having worked as a journalist for Voice of America and the Associated Press. She has been awarded Lifetime Achievement Awards by the American Society of Mechanical Engineers and the Earth Engineering Center Award from Columbia University. Ms. Zannes received her J.D. from the University of Puget Sound in Washington State and is licensed to practice law in New Mexico. bioAffinity Technologies, Inc. (Nasdaq: BIAF)Lung cancer remains the leading cause of cancer deaths worldwide with an estimated 1.8 million deaths annually. Diagnosing and treating early-stage lung cancer can significantly improve outcomes and increase patient survival. bioAffinity Technologies addresses the urgent need for noninvasive, accurate early-stage lung cancer diagnosis. The Company's lead product, CyPath® Lung, accurately detects early-stage lung cancer in high-risk patients as early as Stage 1A. Using CyPath® Lung as part of the diagnostic pathway can lead to earlier diagnosis, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs for the world's largest cancer killer. CyPath® Lung is sold as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a bioAffinity Technologies company, and reimbursed by Medicare, private payors and federal healthcare systems, including the VA. CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to detect cancer by analyzing the lung microenvironment. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in individuals with small indeterminate pulmonary nodules that often pose diagnostic challenges. The test provides actionable information for physicians to guide next steps in patient care. Physicians using CyPath® Lung for their high-risk patients have reported multiple case studies in which CyPath® Lung detected lung cancer at Stage 1A when standard imaging, risk calculator models and serum marker tests indicated the nodules were likely benign. Conversely, a negative CyPath® Lung result has spared many patients from unnecessary and sometimes risky invasive procedures, including biopsy.

China has moved from a fast-following biotech market to a source of globally competitive innovation, according to Josh Smiley, president and chief operating officer of Zai Lab. Speaking on The Top Line podcast, Smiley traces the country’s evolution over the past two decades, pointing to regulatory harmonization, expanded national insurance coverage and deepening R&D capabilities as key drivers. He said the most recent wave of Chinese biotechs is no longer focused solely on domestic opportunities but on first- or best-in-class medicines that can compete worldwide, particularly in oncology and immunology. Smiley also details how Zai Lab blends China’s patient access and development speed with global clinical and regulatory standards, a model he says has helped accelerate programs such as Zai’s DLL3-targeted antibody-drug conjugate for small cell lung cancer into late-stage trials. As China-sourced deals now account for a growing share of global biotech partnerships, Smiley argues companies that integrate China early — without treating it as a standalone market — will have a strategic edge. The conversation offers a candid look at what’s next for Zai Lab and why China’s expanding role in drug innovation is likely to reshape the global pipeline for years to come.See omnystudio.com/listener for privacy information.

Jessie Beltran, investigator and expert on directed energy weapons, joins the program to break down the reality behind nanotechnology findings reported in humans around the world—what is known, what is misunderstood, and what evidence actually exists.Beltran is the technical lead of Mind Nexus, an organization dedicated to uncovering hidden technologies, documenting tangible and verifiable evidence, and supporting individuals affected by directed energy exposure and Havana Syndrome / AHI-related phenomena.In this conversation, we explore the technical mechanisms behind these claims, how directed energy research has evolved, what legitimate concerns exist, and where speculation diverges from provable data. Beltran also shares details about Mind Nexus's upcoming documentary and their ongoing investigative work.Learn more about their research and the upcoming documentary at: https://MindNexusLive.comLinks mentioned in the show:Sign up for my newsletter, see exclusives and more at SarahWestall.Substack.comMasterpeace: Protect your body, Remove Heavy Metals including Graphene Oxide and Plastics, and learn more about removing MAC IDs at  https://masterpeacebyhcs.com/shop/?ref=11308Consider subscribing:Follow on TwitterX @Sarah_WestallFollow on my Substack at SarahWestall.Substack.com

When neuroscientist Madeline Lancaster was a brand new postdoc, she accidentally used an expired protein gel in a lab experiment and noticed something weird. The stem cells she was trying to grow in a dish were self-assembling. The result? Madeline was the first person ever to grow what she called a “cerebral organoid,” a tiny, 3D version of a human brain the size of a peppercorn.In about a decade, these mini human brain balls were everywhere. They were revealing bombshell secrets about how our brains develop in the womb, helping treat advanced cancer patients, being implanted into animals, even playing the video game Pong. But what are they? Are these brain balls capable of sensing, feeling, learning, being? Are they tiny, trapped humans? And if they were, how would we know?Special thanks to Lynn Levy, Jason Yamada-Hanff, David Fajgenbaum, Andrew Verstein, Anne Hamilton, Christopher Mason, Madeline Mason-Mariarty, the team at the Boston Museum of Science, and Howard Fine, Stefano Cirigliano, and the team at Weill-Cornell. EPISODE CREDITS: Reported by - Latif Nasserwith help from - Mona MadgavkarProduced by - Annie McEwen, Mona Madgavkar, and Pat Walterswith mixing help from - Jeremy BloomFact-checking by - Natalie Middleton and Rebecca Randand Edited by  - Alex Neason and Pat WaltersEPISODE CITATIONS:Videos - “Growing Mini Brains to Discover What Makes Us Human,” Madeline Lancaster's TEDxCERN Talk, Nov 2015 (https://zpr.io/6WP7xfA27auR)Brain cells playing Pong (https://zpr.io/pqgSqguJeAPK)Reuters report on CL1 computer launch in March 2025 (https://zpr.io/cdMf8Yjvayyd) Articles - Madeline Lancaster: The accidental organoid – mini-brains as models for human brain development (https://zpr.io/nnwFwUwnm2p6), MRC Laboratory of Molecular Biology What We Can Learn From Brain Organoids (https://zpr.io/frUfsg4pxKsb), by Carl Zimmer. NYT, November 6, 2025Ethical Issues Related to Brain Organoid Research (https://zpr.io/qyiATHEhdnSa), by Insoo Hyun et al, Brain Research, 2020 Brain organoids get cancer, too, opening a new frontier in personalized medicine (https://zpr.io/nqMCQ) STAT Profile of Howard Fine and his lab's glioblastoma research at Weill Cornell Medical Center: By re-creating neural pathway in dish, Stanford Medicine research may speed pain treatment (https://zpr.io/UnegZeQZfqn2) Stanford Medicine profile of Sergiu Pasca's research on pain in organoids A brief history of organoids (https://zpr.io/waSbUCSrL9va) by Corrò et al, American Journal of Physiology - Cell Physiology, Books - Carl Zimmer Life's Edge: The Search for What it Means to be Alive (https://carlzimmer.com/books/lifes-edge/)Sign up for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Signup (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

In this episode of Disruption/Interruption, host KJ sits down with Jurek Kozyra, founder and CEO of Nanovery, to explore how DNA nanotechnology and AI are revolutionizing molecular medicine. Discover how tiny nanorobots made from DNA could dramatically accelerate drug development, make diagnostics faster and more affordable, and potentially cure diseases that were previously untreatable. From detecting diseases in hours instead of days to cutting years off the drug development process, this conversation reveals the cutting-edge science that's transforming healthcare. Four Key Takeaways: The Promise of Oligonucleotide Therapeutics (9:06) Traditional medicine targets defective proteins, but many diseases can't be cured because we can't find the right molecule. Oligonucleotide therapeutics target mRNA—the underlying mechanism of disease—meaning you could potentially cure all diseases since all proteins come from mRNA. DNA Nanorobots for Rapid Detection (14:12) Nanovery's DNA nanorobots can detect diseases in blood samples within 2-4 hours compared to traditional lab tests that take two days. These self-assembling machines produce fluorescent signals when they find specific DNA or RNA molecules, enabling point-of-care diagnostics. Accelerating Drug Development (17:13) Pharmaceutical companies race against 20-year patents while drugs take 10+ years to develop. Nanovery's technology provides more accurate data at lower cost and time, potentially shaving years off the development process and helping more drugs successfully reach the market. Real-World Clinical Validation (20:26) In a hospital study with 170 patient samples, Nanovery's technology delivered same or better results than traditional tests in just two hours instead of two days—a game-changer for emergency situations like drug overdoses where immediate answers are critical. Quote of the Show (9:05):"If you can target mRNA very specifically, that means that in theory you could potentially cure all diseases. That's why this area is so exciting right now." – Jurek Kozyra Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jurek Kozyra: LinkedIn: https://www.linkedin.com/in/j3ny/ Company Website: https://nanovery.co.uk How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Welcome to this special episode of The Edge of Show, recorded live at the Future of Money, Governance & the Law Summit in Washington, D.C. In this episode, we dive deep into the transformative world of tokenization, exploring its impact on real estate, commodities, and beyond. Join our distinguished panel, moderated by Gerard Dache, featuring industry leaders like Benjamin Diggles, Jack Ding, Chris Smithmyer and Nadia Mihova.Key topics include:The difference between coins and tokensInfrastructure requirements for successful tokenizationReal estate tokenization and its potential to revolutionize transactionsThe importance of trust and governance in blockchain technologyInsights into the Blockchain Maturity Model and its role in selecting the right blockchainTogether, they discuss the essential technology infrastructure for tokenization, real-world use cases, and the future of blockchain in various industries.Don't forget to subscribe, rate, and share this episode with friends who are eager to learn more about the cutting edge of Web3!Support us through our Sponsors! ☕

On this week's Tech Nation, with the 44th Annual J.P. Morgan Healthcare Conference around the corner, we delve into three ongoing efforts in biotech. Moira speaks with Cyriac Roeding and Dr David Suhy, Co-Founders of Earli, about their innovative approach to treating solid tumour cancer. Then, Ketan Mehta of Tris Pharma discusses the potential of a euphoria-suppressing opioid. And Neil Klompas of Augurex Life Sciences talks about a new diagnostic for patients with chronic back pain that pinpoints an easily-missed form of arthritis.BTN TITLE: Can Cancer Cells be Turned Against Themselves?This week on BioTech Nation, Moira speaks with Cyriac Roeding and Dr David Suhy, Co-Founders of Earli, about an innovative new approach to solid tumour cancer. They discuss their effort to turn the cancer cells inside solid tumours into factories that produce their own cancer-fighting therapies.

Trevor Maxwell lived the archetype of masculinity in rural Maine. Big, strong, splitting wood, raising kids, and carrying the load. Then cancer ripped that script apart. In 2018 he was bedridden, emasculated, ashamed, and convinced his family would be better off without him. His wife refused to let him disappear. That moment forced Trevor to face his depression, get help, and rebuild himself. Out of that came Man Up To Cancer, now the largest community for men with cancer, a place where men stop pretending they are bulletproof and start being honest with each other.Eric Charsky joins the conversation. A veteran with five cancers, forty-nine surgeries, and the scars to prove it, Eric lays out what happens when the military's invincible mindset collides with mortality. Together, we talk masculinity, vulnerability, sex, shame, and survival. This episode is blunt, raw, and overdue.RELATED LINKSMan Up To CancerTrevor Maxwell on LinkedInDempsey CenterEric Charsky on LinkedInStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The New Year begins with biotech running along parallel storylines. There's cause for optimism as the industry's financing gears have begun to churn again and innovation remains as strong as it has ever been, while there's cause for concern as the world's most stable, progressive, science-based regulatory system has become unpredictable amid new leadership at HHS, FDA, and NIH. On the first episode of the BioCentury This Week podcast's seventh year, BioCentury's analysts assess the state of play for biotech in the U.S., Europe, and Asia.The discussion ranges from recent changes at NIH to what's next for rare pediatric disease priority review vouchers, and from Europe's opportunity as FDA enters uncertain terrain to Japan's evolving biotech landscape.Early bird rates for BioCentury and BayHelix's fifth East-West Biopharma Summit end Friday. Act now to join investors, dealmakers and innovators in Seoul this March to source innovation from Asia, or accelerate your own pipeline by finding the right Asia partner.View full story: https://www.biocentury.com/article/657978#BiotechOutlook #FDAUncertainty #GlobalBiotech #RarePediatricDiseasePRV #NIHLeadership00:00 - Introduction01:46 - 2026 Outlook03:56 - Policy Landscape11:48 - Priority Review Vouchers15:03 - Global Perspectives16:57 - Spotlight on Japan21:55 - European Biotech OpportunitiesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In der ersten Folge des neuen Jahres liefern die Finanzjournalisten Dietmar Deffner und Holger Zschäpitz wieder ihre 26 Investment-Ideen für das Börsenjahr 2026. Der Anspruch ist hoch: In den vergangenen drei Jahren erzielten die Ideen im Schnitt deutlich zweistellige Renditen. Jetzt geht es darum, diese Erfolgsserie fortzuschreiben. DEFFNER & ZSCHÄPITZ sind wie das wahre Leben. Wie Optimist und Pessimist. Im wöchentlichen WELT-Podcast diskutieren und streiten die Journalisten Dietmar Deffner und Holger Zschäpitz über die wichtigen Wirtschaftsthemen des Alltags. Schreiben Sie uns an: wirtschaftspodcast@welt.de Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

As we all learned in 2020, getting ahead of the next major pandemic is a matter of global concern. For the Coalition for Epidemic Preparedness Innovations, or CEPI (cepi.net), it is their reason for existing. Joining me for this conversation are Valentina Bernasconi, Head of Laboratory Science for CEPI, and Marie-Eve Poupart, Lead Scientist In Charles River's Immunology department. Together we discuss CEPI's progress so far, how Charles River is contributing to the cause, and how we can plan for the unknown Disease X while simultaneously handling current outbreaks of deadly diseases like Ebola, Marburg, Nipah virus, Lassa Fever, and chikungunya.

We love to hear from our listeners. Send us a message. This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry trends, new developments, and policy surprises from their respective coverage areas. Topics include biotech funding dynamics, FDA leadership, China's growing role, favorite holiday movies, and much, much more. Special thanks to Tyler Menichiello and the Better Biopharma podcast for hosting this roundtable discussion. Happy New Year!     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Michele Schneider with MarketGuage explains the themes she's watching in what she calls a "fire horse" market this year. She likes robotics, biotech and crypto heading into 2026 and has an eye on small caps. However, Michele urges investors watch for persistent inflation and price impact on everyday goods as a test against American consumers. ======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Welcome to this special episode of The Edge of Show, recorded live at the Future of Money, Governance & the Law Summit in Washington, D.C. This conversation brings together leaders from Web3, finance, policy, and infrastructure to tackle a critical question: how do we fund innovation while building long-term trust, inclusion, and resilience?Moderated by Nadya Rousseau, this panel features Vincent Kadar, Kevin Jackson, Andrew Durgee, and Terry Culver, offering rare insight into how capital formation is evolving through tokenization, public-private collaboration, decentralized infrastructure, and access to private markets.The discussion explores real-world asset tokenization, the role of regulation, the limits of first-mover advantage, and why collaboration, not isolation, is becoming the defining strategy for sustainable innovation. From retail access to pre-IPO assets to DAOs, grants, and hybrid funding models, this episode breaks down how Web3 is reshaping who gets to participate in the global economy.If you're building, investing, shaping policy, or trying to understand where finance and innovation are heading next, this episode delivers clear perspectives from leaders actively building the future not theorizing about it.Support us through our Sponsors! ☕

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When a high-achieving scientist realized the traditional definition of success no longer fit, she chose a radically different path. In this episode, Brie shares how she walked away from a predictable biotech career, trusted her instincts, and built a portfolio-style consulting business that aligns with her values, energy, and love for animal welfare.   What you'll learn How to recognize when your "successful" career no longer feels meaningful Why trusting your instincts is essential when your values begin to shift How career experiments (like Social Goldilocks) can reveal unexpected paths What it takes to design a more flexible, values-aligned version of success   Our book, Happen To Your Career: An Unconventional Approach To Career Change and Meaningful Work, is now available on audiobook! Visit  happentoyourcareer.com/audible to order it now! Visit happentoyourcareer.com/book for more information or buy the print or ebook here! Want to chat with our team about your unique situation? Schedule a conversation   Free Resources What career fits you? Join our free 8 Day Mini Course to figure it out! Career Change Guide - Learn how high-performers discover their ideal career and find meaningful, well-paid work without starting over.   Related Episodes Designing Career Experiments and Testing New Careers (Spotify / Apple Podcasts) Discover Your Strengths to Find Your Ideal Career (Spotify / Apple Podcasts) Social Goldilocks Experiment (Watch Here)

A Note from James:One of my favorite conversations on this show was with Peter Thiel. Yes—PayPal, Facebook, Palantir, and a dozen other hits. I first ran this episode years ago, and the advice still holds up. The same stories, the same frameworks—and the same challenge to think from first principles. Here's Peter Thiel, one of the most influential entrepreneurs of our time. Episode Description:In this redux, James pressure-tests the core ideas from Peter Thiel's Zero to One—why competition is for losers, how real monopolies are built, and why starting “narrow” is often the only path to something huge. They cover Facebook's early moat (real identity), PayPal's network-effect wedge on eBay, and the “10x or nothing” bar for proprietary technology. Peter shares a contrarian read on bubbles, why biotech's slump may be opportunity, and how to hire, divide roles, and keep teams from fighting. The through-line: seek secrets, combine disciplines, and make something so different that it becomes its own category. What You'll Learn:How to pick markets the Zero to One way: start with a “small, winnable monopoly,” then expand in concentric circles. The four classic moats—and which to favor first: proprietary tech, network effects, economies of scale, and brand (with a bias toward real tech). A practical rule for virality vs. network effects: growth is a tactic; enduring value comes from the network that forms once users arrive. Team design that prevents internal warfare: make roles uniquely owned; if two people own the same thing, you're paying for a fight. How to hunt “secrets”: believe they exist, look where consensus is stale, and borrow from adjacent fields to see what specialists miss. Timestamped Chapters:[02:00] A Note from James — Why this conversation still ranks among the best. [03:00] Zero to One, in one line — “Do something new, different, fresh, strange.” [05:17] Competition vs. Capitalism — Why perfect competition kills profits; aim for uniqueness. [07:28] Facebook's original edge — Real identity as the breakthrough vs. MySpace's alt-persona culture. [09:14] Bits vs. Atoms — Stagnation outside software and how biology could become an information science. [12:05] Personality and perseverance — Why mild contrarian wiring helps founders ignore status games. [15:21] “10x or nothing” — The technology and/or experience must be an order of magnitude better. [17:00] Monopoly thinking, ethically done — Create abundance by creating something truly new. [23:30] The PayPal pre-history — Why long-running trust among teammates births more companies. [30:10] Early Facebook investment logic — College-only looked “small,” which was exactly the point. [32:03] Turning down $1B — The boardroom debate, optionality, and founder conviction. [36:23] Moats in practice — Picking the right advantage (and why brand alone is shaky). [37:06] Network effects ≠ virality — How value compounds after growth. [39:54] PayPal's wedge — eBay power-sellers and the $10 incentive as a growth accelerant. [41:22] Beware the “Chinese refrigerator” TAM slide — Start small, win big. [42:01] Uber vs. Airbnb — Investor bias and why some models get over- or undervalued. [44:18] Bubbles and the public — What changes across tech, housing, and today's “government bubble.” [48:00] War on cash & credit — Why Peter favors unlevered, opaque innovation over fixed income. [51:10] Biotech headwinds (and upside) — Regulation, Eroom's Law, and why sentiment can misprice breakthroughs. [53:50] Secrets — If you assume they exist, you'll be the one to find them. [57:56] Interdisciplinary bets — CS × biology; CS × transportation; why university silos miss the action. [59:51] Silicon Valley on HBO — The “Peter Gregory” caricature and what the show gets right. Additional Resources:Zero to One: Notes on Startups, or How to Build the Future (book) — Amazon hardcover. AmazonFounders Fund — Peter Thiel profile (bio & portfolio highlights). Founders Fund“PayPal Mafia” overview (alumni companies: YouTube, Yelp, LinkedIn, Tesla, SpaceX, Palantir, Yammer). WikipediaYahoo's 2006 $1B offer for Facebook (background reporting). Business InsiderEroom's Law (pharma R&D productivity; Nature Reviews Drug Discovery). NatureSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.